169 related articles for article (PubMed ID: 32918998)
1. New hints towards a precision medicine strategy for IDH wild-type glioblastoma.
White K; Connor K; Clerkin J; Murphy BM; Salvucci M; O'Farrell AC; Rehm M; O'Brien D; Prehn JHM; Niclou SP; Lamfers MLM; Verreault M; Idbaih A; Verhaak R; Golebiewska A; Byrne AT
Ann Oncol; 2020 Dec; 31(12):1679-1692. PubMed ID: 32918998
[TBL] [Abstract][Full Text] [Related]
2. Molecular Evolution of
Draaisma K; Chatzipli A; Taphoorn M; Kerkhof M; Weyerbrock A; Sanson M; Hoeben A; Lukacova S; Lombardi G; Leenstra S; Hanse M; Fleischeuer R; Watts C; McAbee J; Angelopoulos N; Gorlia T; Golfinopoulos V; Kros JM; Verhaak RGW; Bours V; van den Bent MJ; McDermott U; Robe PA; French PJ
J Clin Oncol; 2020 Jan; 38(1):81-99. PubMed ID: 31743054
[TBL] [Abstract][Full Text] [Related]
3. O
Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
[TBL] [Abstract][Full Text] [Related]
4. Management of glioblastoma: State of the art and future directions.
Tan AC; Ashley DM; López GY; Malinzak M; Friedman HS; Khasraw M
CA Cancer J Clin; 2020 Jul; 70(4):299-312. PubMed ID: 32478924
[TBL] [Abstract][Full Text] [Related]
5. Targeted anticonvulsive treatment of IDH-wildtype glioblastoma based on DNA methylation subclasses.
Drexler R; Göttsche J; Sauvigny T; Schüller U; Khatri R; Hausmann F; Hänzelmann S; Huber TB; Bonn S; Heiland DH; Delev D; Venkataramani V; Winkler F; Weller J; Zeyen T; Herrlinger U; Gempt J; Ricklefs FL; Dührsen L
Neuro Oncol; 2023 May; 25(5):1006-1008. PubMed ID: 36860191
[No Abstract] [Full Text] [Related]
6. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
[TBL] [Abstract][Full Text] [Related]
7. Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification.
Wenger A; Ferreyra Vega S; Kling T; Bontell TO; Jakola AS; Carén H
Neuro Oncol; 2019 May; 21(5):616-627. PubMed ID: 30668814
[TBL] [Abstract][Full Text] [Related]
8. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
9. Integrated molecular characterization of IDH-mutant glioblastomas.
Korshunov A; Casalini B; Chavez L; Hielscher T; Sill M; Ryzhova M; Sharma T; Schrimpf D; Stichel D; Capper D; Reuss DE; Sturm D; Absalyamova O; Golanov A; Lambo S; Bewerunge-Hudler M; Lichter P; Herold-Mende C; Wick W; Pfister SM; Kool M; Jones DTW; von Deimling A; Sahm F
Neuropathol Appl Neurobiol; 2019 Feb; 45(2):108-118. PubMed ID: 30326163
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI
Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of IDH 1 mutation in patients with glioblastoma multiforme.
Khan I; Waqas M; Shamim MS
J Pak Med Assoc; 2017 May; 67(5):816-817. PubMed ID: 28507382
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
13. Updates in IDH-Wildtype Glioblastoma.
Melhem JM; Detsky J; Lim-Fat MJ; Perry JR
Neurotherapeutics; 2022 Oct; 19(6):1705-1723. PubMed ID: 35641844
[TBL] [Abstract][Full Text] [Related]
14. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
[TBL] [Abstract][Full Text] [Related]
15. Computational Characterization of Suppressive Immune Microenvironments in Glioblastoma.
Luoto S; Hermelo I; Vuorinen EM; Hannus P; Kesseli J; Nykter M; Granberg KJ
Cancer Res; 2018 Oct; 78(19):5574-5585. PubMed ID: 29921698
[TBL] [Abstract][Full Text] [Related]
16. Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status.
Wee CW; Kim E; Kim N; Kim IA; Kim TM; Kim YJ; Park CK; Kim JW; Kim CY; Choi SH; Kim JH; Park SH; Choe G; Lee ST; Chang JH; Kim SH; Suh CO; Kim IH
Radiother Oncol; 2017 Apr; 123(1):106-111. PubMed ID: 28302331
[TBL] [Abstract][Full Text] [Related]
17. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
[TBL] [Abstract][Full Text] [Related]
18. [Advance of molecular subtyping and precise treatment for gliomas].
Hua W; Mao Y
Zhonghua Wai Ke Za Zhi; 2017 Jan; 55(1):63-66. PubMed ID: 28056258
[TBL] [Abstract][Full Text] [Related]
19. Isocitrate dehydrogenase mutations in defining the biology of and supporting clinical decision making in glioblastoma.
Kálovits F; Tompa M; Nagy Á; Kálmán B
Ideggyogy Sz; 2018 Jul; 71(7-08):237-247. PubMed ID: 30113792
[TBL] [Abstract][Full Text] [Related]
20.
Juratli TA; Stasik S; Zolal A; Schuster C; Richter S; Daubner D; Juratli MA; Thowe R; Hennig S; Makina M; Meinhardt M; Lautenschlaeger T; Schackert G; Krex D; Thiede C
Clin Cancer Res; 2018 Nov; 24(21):5282-5291. PubMed ID: 29941484
[No Abstract] [Full Text] [Related]
[Next] [New Search]
